These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35234840)

  • 1. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
    Obeid S; Libby P; Husni E; Wang Q; Wisniewski LM; Davey DA; Wolski KE; Xia F; Bao W; Walker C; Ruschitzka F; Nissen SE; Lüscher TF
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):611-621. PubMed ID: 35234840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
    Nissen SE; Yeomans ND; Solomon DH; Lüscher TF; Libby P; Husni ME; Graham DY; Borer JS; Wisniewski LM; Wolski KE; Wang Q; Menon V; Ruschitzka F; Gaffney M; Beckerman B; Berger MF; Bao W; Lincoff AM;
    N Engl J Med; 2016 Dec; 375(26):2519-29. PubMed ID: 27959716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.
    Ruschitzka F; Borer JS; Krum H; Flammer AJ; Yeomans ND; Libby P; Lüscher TF; Solomon DH; Husni ME; Graham DY; Davey DA; Wisniewski LM; Menon V; Fayyad R; Beckerman B; Iorga D; Lincoff AM; Nissen SE
    Eur Heart J; 2017 Nov; 38(44):3282-3292. PubMed ID: 29020251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
    Solomon DH; Husni ME; Wolski KE; Wisniewski LM; Borer JS; Graham DY; Libby P; Lincoff AM; Lüscher TF; Menon V; Yeomans ND; Wang Q; Bao W; Berger MF; Nissen SE;
    Arthritis Rheumatol; 2018 Apr; 70(4):537-546. PubMed ID: 29266879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
    Eccleston C; Cooper TE; Fisher E; Anderson B; Wilkinson NM
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012537. PubMed ID: 28770976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
    Solomon DH; Husni ME; Libby PA; Yeomans ND; Lincoff AM; Lϋscher TF; Menon V; Brennan DM; Wisniewski LM; Nissen SE; Borer JS
    Am J Med; 2017 Dec; 130(12):1415-1422.e4. PubMed ID: 28756267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
    Yeomans ND; Graham DY; Husni ME; Solomon DH; Stevens T; Vargo J; Wang Q; Wisniewski LM; Wolski KE; Borer JS; Libby P; Lincoff AM; Lüscher TF; Bao W; Walker C; Nissen SE;
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1453-1463. PubMed ID: 29667211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen.
    Reed GW; Abdallah MS; Shao M; Wolski K; Wisniewski L; Yeomans N; Lüscher TF; Borer JS; Graham DY; Husni ME; Solomon DH; Libby P; Menon V; Lincoff AM; Nissen SE
    J Am Coll Cardiol; 2018 Apr; 71(16):1741-1751. PubMed ID: 29673465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
    Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE;
    Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).
    MacDonald TM; Hawkey CJ; Ford I; McMurray JJV; Scheiman JM; Hallas J; Findlay E; Grobbee DE; Hobbs FDR; Ralston SH; Reid DM; Walters MR; Webster J; Ruschitzka F; Ritchie LD; Perez-Gutthann S; Connolly E; Greenlaw N; Wilson A; Wei L; Mackenzie IS
    Eur Heart J; 2017 Jun; 38(23):1843-1850. PubMed ID: 27705888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiorenal Safety of OTC Analgesics.
    White WB; Kloner RA; Angiolillo DJ; Davidson MH
    J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):103-118. PubMed ID: 29421936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
    Dong YH; Chang CH; Wu LC; Hwang JS; Toh S
    Br J Clin Pharmacol; 2018 May; 84(5):1045-1056. PubMed ID: 29468706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
    Chan FKL; Ching JYL; Tse YK; Lam K; Wong GLH; Ng SC; Lee V; Au KWL; Cheong PK; Suen BY; Chan H; Kee KM; Lo A; Wong VWS; Wu JCY; Kyaw MH
    Lancet; 2017 Jun; 389(10087):2375-2382. PubMed ID: 28410791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
    Whelton A; Lefkowith JL; West CR; Verburg KM
    Kidney Int; 2006 Oct; 70(8):1495-502. PubMed ID: 16941030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
    Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.